[CAS NO. 61177-44-4] Clavulanatelithium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [61177-44-4]

Catalog

HY-A0256B

Brand

MCE

CAS

61177-44-4

DESCRIPTION [61177-44-4]

Overview

MDL	MFCD22666231
Molecular Weight	205.09
Molecular Formula	C8H8LiNO5
SMILES	O=C([C@@H](/C(O[C@]1([H])C2)=C/CO)N1C2=O)O[Li]

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Clavulanate lithium is a potent β-lactamase inhibitor and acts as an antibiotic ^[1] ^[2] .

IC50 & Target

β-lactamase ^[1]

In Vitro

Clavulanate lithium has weak antibacterial activity against most organisms when administered alone, but given in combination with beta-lactam antibiotics prevents antibiotic inactivation by microbial lactamase ^[1] .
Clavulanate lithium (0.25, 0.5 mg/L) causes a relatively slow inhibition of growth, and a higher concentration (1 mg/L) is only marginally more effective than 0.5 mg/L ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	L. pneumophila NCTC 1119
Concentration:	0.25 mg/L, 0.5 mg/L, 1 mg/L
Incubation Time:	0-35 hours
Result:	Caused a relatively slow inhibition of growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04411914	Temple University\|Beth Israel Deaconess Medical Center\|University of Pennsylvania Perelman School of Medicine	Cocaine Dependence	September 1, 2020	Phase 1
NCT03986762	Temple University\|National Institute on Drug Abuse (NIDA)	Cocaine Dependence, in Remission\|Cocaine Abuse, in Remission\|Cocaine-Related Disorders	March 12, 2019	Phase 1
NCT02007603	Medical University of Vienna	Infection During Hemodialysis	August 2013	Phase 3
NCT01096927	Maggiore Bellaria Hospital, Bologna	Lower Abdominal Pain\|Right Iliac Fossa Pain\|Acute Appendicitis	January 2010	Phase 4
NCT00917592	Consorci Sanitari de Terrassa\|Corporacion Parc Tauli	Diverticulitis	December 2005	Phase 4
NCT04400110	IRCCS Burlo Garofolo	Urinary Tract Infections	June 8, 2020	Phase 4
NCT05079620	UConn Health	Aspiration\|Aspiration Pneumonia	November 30, 2021	Phase 4
NCT01015417	Centre Hospitalier Universitaire, Amiens	Acute Lithiasic Cholecystitis Grade I or II\|Symptoms Lasting for Less Than 5 Days\|Required Cholecystectomy\|Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days	May 2010	Phase 3
NCT00495586	Catalan Society of Family Medicine\|Fondo de Investigacion Sanitaria	Chronic Obstructive Pulmonary Disease	October 2007	Phase 4
NCT02571959	Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba	Obesity	July 24, 2015	Phase 1\|Phase 2
NCT05562349	Temple University\|University of Pennsylvania Perelman School of Medicine\|Medical University of South Carolina\|Research Foundation for Mental Hygiene, Inc.	Cocaine Dependence	October 2022	Phase 2
NCT02563769	Temple University\|National Institute on Drug Abuse (NIDA)\|University of Pennsylvania	Cocaine Dependence\|Cocaine Addiction\|Cocaine Abuse\|Cocaine-Related Disorders	September 2016	Phase 1
NCT02186951	University Hospital, Limoges	Ventilator-associated Pneumonia\|Cardiac Arrests With Shockable Rhythm\|Mild Therapeutic Hypothermia\|Preventive Antibiotics	August 18, 2014	Phase 3
NCT03809312	CHU de Quebec-Universite Laval	Chronic Sinus Infection	August 14, 2019	Phase 4
NCT04980170	Jordan University Hospital	Antibiotics Causing Adverse Effects in Therapeutic Use	November 1, 2021	Early Phase 1
NCT00656747	Bayer	Chronic Bronchitis	March 2008	Phase 4
NCT00665873	Universita degli Studi di Catania	Infections	January 2004	Phase 4
NCT04350502	Centre Hospitalier Universitaire, Amiens	Pleural Infection\|Empyema\|Community-acquired Pneumonia\|Pharmacokinetic\|Amoxicillin	April 4, 2020	Not Applicable
NCT03713424	University of Missouri-Columbia	Tobacco Use Disorder	March 26, 2019	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 33.33 mg/mL ( 162.51 mM ; Need ultrasonic)

DMSO : 4.17 mg/mL ( 20.33 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.8759 mL	24.3795 mL	48.7591 mL
5 mM	0.9752 mL	4.8759 mL	9.7518 mL
10 mM	0.4876 mL	2.4380 mL	4.8759 mL

* Please refer to the solubility information to select the appropriate solvent.

References

Synonyms

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, lithium salt (1:1), (2R,3Z,5R)-

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monolithium salt, [2R-(2α,3Z,5α)]-

4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monolithium salt, (2R,3Z,5R)-

Lithium clavulanate